Lingzhi Zhao

Lingzhi Zhao

Company: AGTC

Job title: Senior Director - Gene Therapy & Transnational Discovery


AAVrh10-based Gene Therapy for the Treatment of Frontotemporal Dementia Caused by GRN Mutations 5:00 pm

Dominant mutations in granulin (GRN) gene accounts for up to 10% of frontotemporal dementia (FTD) and results in > 50% reduction of progranulin (PGRN) expression in patients Adeno-associated virus (AAV) gene therapy to booster the levels of progranulin may represent a feasible strategy to treat FTD-GRN AGTC-601 is an AAV gene therapy to supplement progranulin…Read more

day: Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.